{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:37:19Z","timestamp":1790869039809,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.coph.2020.10.009","type":"journal-article","created":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T08:34:59Z","timestamp":1605342899000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9792-5605","authenticated-orcid":false,"given":"Murugesan","family":"Vanangamudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Kurup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigneshwaran","family":"Namasivayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2020.10.009_bib0005","series-title":"NanoBioMedicine","first-page":"167","article-title":"HIV: biology to treatment","author":"Verma","year":"2020"},{"key":"10.1016\/j.coph.2020.10.009_bib0010","unstructured":"UNAIDS 2019. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2019-UNAIDS-data_en.pdf."},{"key":"10.1016\/j.coph.2020.10.009_bib0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Xavier Ruiz","year":"2020","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.coph.2020.10.009_bib0020","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.coph.2020.10.009_bib0025","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1021\/acs.jmedchem.9b00175","article-title":"Fifty years in search of selective antiviral drugs","volume":"62","author":"De Clercq","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2020.10.009_bib0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2020.10.009_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2020.10.009_bib0040","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","article-title":"The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals","volume":"14","author":"van Heeswijk","year":"2000","journal-title":"Aids"},{"key":"10.1016\/j.coph.2020.10.009_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2007.00426.x","article-title":"Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review","volume":"8","author":"Cooper","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.coph.2020.10.009_bib0050","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003495-200060060-00013","article-title":"Delavirdine: a review of its use in HIV infection","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.10.009_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003088-200140030-00005","article-title":"Delavirdine: clinical pharmacokinetics and drug interactions","volume":"40","author":"Tran","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2020.10.009_bib0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.10.009_bib0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/dmd.119.086348","article-title":"Efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.coph.2020.10.009_bib0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/11209110-000000000-00000","article-title":"Etravirine","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.10.009_bib0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp080559","article-title":"Etravirine: a novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection","volume":"67","author":"Elsayed","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.coph.2020.10.009_bib0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40262-019-00830-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of Etravirine: an updated review","volume":"59","author":"Havens","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2020.10.009_bib0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1592\/phco.29.3.281","article-title":"Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents","volume":"29","author":"Fulco","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.coph.2020.10.009_bib0090","doi-asserted-by":"crossref","first-page":"156","DOI":"10.24875\/AIDSRev.M17000005","article-title":"Rilpivirine: the key for long-term success","volume":"19","author":"Viciana","year":"2017","journal-title":"AIDS Rev"},{"key":"10.1016\/j.coph.2020.10.009_bib0095","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","article-title":"Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of Doravirine","volume":"58","author":"Boyle","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2020.10.009_sbref0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1358\/dot.2020.56.2.3109966","article-title":"Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection","volume":"56","author":"Talwani","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.coph.2020.10.009_bib0105","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2019-11-4","article-title":"Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection","volume":"9","author":"Pham","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.coph.2020.10.009_bib0110","series-title":"20th International AIDS Conference","article-title":"Parmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients. [abstract no. LBPE20 plus poster]","author":"Ratanasuwan","year":"2014"},{"key":"10.1016\/j.coph.2020.10.009_bib0115","series-title":"Conference on retroviruses and opportunistic Infections (CROI)","article-title":"Elsulfavirine as compared to efavirenz in combination with TDF\/FTC: 48-week Study","author":"Murphy","year":"2017"},{"key":"10.1016\/j.coph.2020.10.009_bib0120","unstructured":"ClinicalTrials.gov. Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03730311. Accessed on April 23, 2019."},{"key":"10.1016\/j.coph.2020.10.009_bib0125","series-title":"Pre-clinical Pharmacokinetics of elsufavirine\/VM1500A Long Acting Injectable Formulations (Poster WEPEA0190)","author":"Rogovoy","year":"2017"},{"key":"10.1016\/j.coph.2020.10.009_bib0130","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s40265-017-0820-3","article-title":"Elsulfavirine: first global approval","volume":"77","author":"Al-Salama","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.10.009_bib0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.20953\/1729-9225-2017-3-5-13","article-title":"Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir\/emtricitabine multicenter comparative trial vs efavirenz in na\u0457ve HIV patients","volume":"15","author":"Kravchenko","year":"2017","journal-title":"Infekc bolezni (Infectious diseases)"},{"key":"10.1016\/j.coph.2020.10.009_bib0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.22625\/2072-6732-2018-10-2-76-82","article-title":"Efficacy and safety of novel Russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with nucleoside\/nucleotide reverse transcriptase inhibitors in first-line HIV treatment \u2013 96-week study","volume":"10","author":"Kravchenko","year":"2018","journal-title":"J Infectol"},{"key":"10.1016\/j.coph.2020.10.009_sbref0145","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2020.10.009_bib0150","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2020.10.009_bib0155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2020.10.009_bib0160","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http:\/\/aidsinfo.nih.gov\/guidelines."},{"key":"10.1016\/j.coph.2020.10.009_bib0165","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14656566.2018.1450866","article-title":"Next generation fixed dose combination pharmacotherapies for treating HIV","volume":"19","author":"Caplan","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coph.2020.10.009_bib0170","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV drug discovery and development: current innovations and future trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2020.10.009_bib0175","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/jac\/dkv429","article-title":"Backbones versus core agents in initial ART regimens: one game, two players","volume":"71","author":"Llibre","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2020.10.009_bib0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40121-020-00290-w","article-title":"Two\u2019s a company, three\u2019s a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-na\u00efve and treatment-experienced patients living with HIV-1","volume":"9","author":"Badowski","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.coph.2020.10.009_bib0185","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s13365-018-0701-x","article-title":"Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience","volume":"25","author":"Arendt","year":"2019","journal-title":"J Neurovirol"},{"key":"10.1016\/j.coph.2020.10.009_bib0190","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and development of anti-HIV therapeutic agents: progress towards improved HIV medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.coph.2020.10.009_bib0195","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-013-0020-8","article-title":"Integrase strand transfer inhibitors in HIV therapy","volume":"2","author":"Mespl\u00e8de","year":"2013","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.coph.2020.10.009_bib0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/jm400674a","article-title":"Inhibiting the HIV integration process: past, present, and the future","volume":"57","author":"Di Santo","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2020.10.009_sbref0205","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40265-019-01247-1","article-title":"Dolutegravir\/lamivudine single-tablet regimen: a review in HIV-1 infection","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2020.10.009_sbref0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2020.10.009_bib0215","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.2147\/DDDT.S140767","article-title":"Two-drug regimens for treatment of na\u00efve HIV-1 infection and as maintenance therapy","volume":"12","author":"Corado","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.coph.2020.10.009_sbref0220","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.coph.2020.10.009_bib0225","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/14787210.2018.1544491","article-title":"Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults","volume":"16","author":"Properzi","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.coph.2020.10.009_bib0230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00748-18","article-title":"Bioequivalence of a fixed-dose combination tablet of the complete two-drug regimen of dolutegravir and rilpivirine for treatment of HIV-1 infection","volume":"62","author":"Mehta","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2020.10.009_bib0235","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2020.10.009_bib0240","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/aid.2016.0291","article-title":"Dual raltegravir-etravirine combination as maintenance regimen in virologically suppressed HIV-1-infected patients","volume":"33","author":"Calza","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coph.2020.10.009_bib0245","first-page":"179","article-title":"Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential","volume":"11","author":"Fernandez","year":"2019","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.coph.2020.10.009_bib0250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40262-016-0458-4","article-title":"A two-way steady-state pharmacokinetic interaction study of doravirine (MK-1439) and dolutegravir","volume":"56","author":"Anderson","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.coph.2020.10.009_bib0255","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/acsmedchemlett.7b00524","article-title":"Discovery of novel diarylpyrimidine derivatives as potent HIV-1 NNRTIs targeting the \u201cNNRTI Adjacent\u201d binding site","volume":"9","author":"Huo","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.coph.2020.10.009_bib0260","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14728214.2018.1474202","article-title":"Emerging reverse transcriptase inhibitors for HIV-1 infection","volume":"23","author":"Rai","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.coph.2020.10.009_sbref0265","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25282","article-title":"Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness","volume":"22","author":"Glaubius","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.coph.2020.10.009_bib0270","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s13346-018-0538-0","article-title":"Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques","volume":"8","author":"Pereira","year":"2018","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.coph.2020.10.009_bib0275","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.02201-15","article-title":"Pharmacokinetic and pharmacodynamic evaluation following vaginal application of IQB3002, a dual-chamber microbicide gel containing the nonnucleoside reverse transcriptase inhibitor IQP-0528 in rhesus macaques","volume":"60","author":"Pereira","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489220301077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:53:06Z","timestamp":1761461586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489220301077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":55,"alternative-id":["S1471489220301077"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.009","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2020.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}